Atopic dermatitis - from new pathophysiologic insights to individualized therapy: Individualized therapy of AD
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Recently, important novel insights into the complex pathophysiology of atopic dermatitis (AD) have been gained. However, in most cases the therapy of AD is limited to base line therapy with emollients combined with symptomatic, rather general immunosuppressive treatment approaches of the flare-ups. Latest research findings together with experiences from daily clinical practice, which support the concept that a combination of general disease features together with specific trigger factors in the individual patients drive the disease, might be helpful for a subclassification of patients with AD based on the most relevant pathophysiologic modifications. Subclassification of patients with AD seems indispensable to introduce rationale-based, individualized treatment approaches of AD, which target specific modified pathways. In this review, we provide an overview about a selection of pathophysiologic pathways, which hold promise to represent targets of such therapeutic approaches in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Korn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 8×
“A new subset of skin-homing memory T cells that are distinct from Th17 cells as they produce IL-22 but no IL-17 or IFN-c have recently been identified (99).”
BackgroundInfluentialLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis
Ong, P. Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., Gallo, R. L., & Leung, D. Y. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021481 · Cited by 1,960 · cited 1×
“When compared to other chronic inflammatory skin diseases such as psoriasis, deficiency of LL-37 and hBD-2 (22) as well as hBD-3 and dermicidin has been observed in AD (23, 24).”
BackgroundImpaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome
Milner, J. D., Brenchley, J. M., Laurence, A., Freeman, A. F., Hill, B. J., Elias, K. M., Kanno, Y., Spalding, C., Elloumi, H. Z., Paulson, M. L., et al. (2008) · Nature · doi:10.1038/nature06764 · Cited by 1,157
Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells
Duhen, T., Geiger, R., Jarrossay, D., Lanzavecchia, A., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1767 · Cited by 1,079 · cited 1×
“A new subset of skin-homing memory T cells that are distinct from Th17 cells as they produce IL-22 but no IL-17 or IFN-c have recently been identified (99).”
BackgroundHeil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197 · cited 3×
“In patients with AD receiving omalizumab dosed according to body weight and IgE levels over 16 weeks, no significant improvement in skin symptoms and pruritus was achieved (82).”
BackgroundInfluentialStaphylococcal exotoxins are strong inducers of IL-22: A potential role in atopic dermatitis
Niebuhr, M., Scharonow, H., Gathmann, M., Mamerow, D., & Werfel, T. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.07.041 · Cited by 110 · cited 1×
“aureus exotoxins significantly enhanced the production of IL-22 by T cells from patients with AD (102).”
Background
Cited by
Immunology of atopic eczema: overcoming the Th1/Th2 paradigm
Eyerich, K., & Novak, N. (2013) · Allergy · doi:10.1111/all.12184 · Cited by 325
Self-citationCharacterization of different courses of atopic dermatitis in adolescent and adult patients
Garmhausen, D., Hagemann, T., Bieber, T., Dimitriou, I., Fimmers, R., Diepgen, T., & Novak, N. (2013) · Allergy · doi:10.1111/all.12112 · Cited by 291
Self-citationFungi: the neglected allergenic sources
Crameri, R., Garbani, M., Rhyner, C., & Huitema, C. (2014) · Allergy · doi:10.1111/all.12325 · Cited by 207
“The pathophysiology of AD, also called atopic eczema, is complex and not fully understood (57).”
BackgroundAtopic dermatitis: a candidate for disease‐modifying strategy
Bieber, T., Cork, M., & Reitamo, S. (2012) · Allergy · doi:10.1111/j.1398-9995.2012.02845.x · Cited by 131
“Thereby, BM will eventually allow to identify subgroups of patients who would have a substantial benefit from distinct therapeutic (10) and prevention approaches, potentially leading to a significant control if not cure of this disease at an early point of time.”
BackgroundHotze, M., Baurecht, H., Rodríguez, E., Chapman‐Rothe, N., Ollert, M., Fölster‐Holst, R., Adamski, J., Illig, T., Ring, J., & Weidinger, S. (2014) · Allergy · doi:10.1111/all.12234 · Cited by 107
Metadata
- Authors
- Novak, N., & Simon, D.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2011-03-03
- Volume
- 66
- Issue
- 7
- Pages
- 830-839
- ISSN
- 0105-4538 (ISSN-L)
- OpenAlex
- W1575753008
- Cited by
- 113
- References
- 7
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.